From: Assessing the validity of tuberculosis surveillance data in California
#* | RVCT Variable | Concordance (95% CI†) % | Sensitivity of Reported Value (95% CI) % | Predictive Value of Reported Positive Value (95% CI) % | |||
---|---|---|---|---|---|---|---|
DEMOGRAPHIC | |||||||
1 | Sex | 98.1 | (96.7, 99.0) | 99.7 | (98.0, 99.9) | 97.5 | (95.3, 98.6) |
2 | Race | 97.7 | (96.3, 98.6) | ND‡ | ND | ND | ND |
White | ND | ND | 99.2 | (97.5, 99.7) | 97.0 | (94.4, 98.4) | |
Black | ND | ND | 95.3 | (87.1, 98.4) | 97.9 | (88.8, 99.7) | |
Asian-Pacific Islander | ND | ND | 97.5 | (94.9, 98.8) | 98.4 | (96.3, 99.3) | |
American Indian/Alaska Native | ND | ND | 50.0 | (12.8, 87.2) | 100.0 | -§ | |
3 | Ethnicity | 98.5 | (97.2, 99.1) | 97.6 | (94.7, 98.9) | 98.1 | (95.5, 99.2) |
Country of origin | |||||||
4 | U.S.-born | 98.9 | (97.7, 99.4) | 99.1 | (95.1, 99.9) | 96.6 | (92.8, 98.4) |
5 | Other country of origin | 96.0 | (93.6, 97.5) | ND | ND | ND | ND |
6 | Occupation | 84.4 | (80.7, 87.5) | ND | ND | ND | ND |
Health care worker | ND | ND | 78.2 | (46.4, 93.7) | 70.5 | (41.3, 89.0) | |
Migratory agricultural worker | ND | ND | 51.8 | (25.1, 77.5) | 81.1 | (38.3, 96.7) | |
Other occupation | ND | ND | 76.4 | (69.8, 81.9) | 89.0 | (83.3, 92.9) | |
Not employed within past 24 months | ND | ND | 93.5 | (89.5, 96.0) | 82.2 | (76.9, 86.5) | |
7 | Resident of long-term care facility at diagnosis | 98.3 | (97.1, 99.0) | 67.8 | (47.1, 83.3) | 76.8 | (57.8, 88.9) |
8 | Resident of correctional facility at diagnosis | 99.0 | (97.7, 99.6) | 69.7 | (45.7, 86.3) | 100.0 | - |
SOCIAL AND BEHAVIORAL RISK FACTORS | |||||||
9 | Homeless within past 1–2 years|| | 99.1 | (96.9, 99.7) | 97.3 | (92.6, 99.0) | 95.1 | (75.9, 99.2) |
10 | Injecting drug user within past year | 98.1 | (96.5, 99.0) | 63.5 | (41.5, 81.0) | 86.5 | (59.8, 96.5) |
11 | Non-injecting drug user within past year | 96.6 | (94.6, 97.9) | 70.1 | (55.2, 81.7) | 90.9 | (74.6, 97.1) |
12 | Excess alcohol use within past year | 91.8 | (88.8, 94.0) | 69.9 | (61.0, 77.6) | 96.8 | (89.3, 99.1) |
DIAGNOSTIC AND CLINICAL | |||||||
13 | Previous TB | 94.6 | (92.3, 96.2) | 57.6 | (45.0, 69.3) | 93.5 | (81.9, 97.9) |
14 | Site of disease | 92.5 | (90.4, 94.2) | ND | ND | ND | ND |
Pulmonary only | ND | ND | 96.7 | (94.6, 97.9) | 96.2 | (94.3, 97.4) | |
Extra-pulmonary only | ND | ND | 98.6 | (96.8, 99.4) | 81.6 | (74.4, 87.0) | |
Both pulmonary and extra-pulmonary | ND | ND | 51.1 | (39.7, 62.4) | 86.9 | (73.9, 94.0) | |
15 | Sputum smear | 89.6 | (86.0, 92.3) | 90.5 | (85.8, 93.7) | 92.2 | (87.9, 95.1) |
16 | Sputum culture | 96.8 | (94.2, 98.2) | 100.0 | - | 96.8 | (94.2, 98.2) |
17 | Smear of tissue/body fluids (non-sputum) | 49.2 | (38.4, 60.0) | 31.2 | (21.0, 43.6) | 98.7 | (98.1, 99.2) |
18 | Tissue/body fluid type (non-sputum) | 76.4 | (59.3, 87.8) | ND | ND | ND | ND |
19 | Culture of tissue/body fluid (non-sputum) | 98.2 | (94.6, 99.4) | 100.0 | - | 98.2 | (94.6, 99.4) |
20 | Tissue/body fluid type (non-sputum) | 73.9 | (66.0, 80.6) | ND | ND | ND | ND |
Chest x-ray | |||||||
21 | Abnormal/normal | 96.0 | (94.0, 97.3) | 99.1 | (97.6, 99.7) | 96.8 | (94.8, 98.0) |
22 | If abnormal: cavitary/non-cavitary** | 90.9 | (88.0, 93.2) | 75.1 | (66.3, 82.3) | 86.2 | (78.0, 91.7) |
23 | If abnormal: stable/worsening/improving | 46.8 | (37.0, 56.9) | ND | ND | ND | ND |
Stable | ND | ND | 49.9 | (36.0, 63.7) | 53.7 | (39.0, 67.9) | |
Worsening | ND | ND | 52.0 | (38.0, 65.7) | 51.7 | (37.8, 65.4) | |
Improving | ND | ND | 26.9 | (8.7, 58.6) | 19.8 | (6.5, 46.8) | |
24 | Initial drug susceptibility testing done | 100.0 | - | 100.0 | - | 100.0 | - |
Results of initial drug susceptibility testing†† | |||||||
25 | Isoniazid | 99.2 | (98.1, 99.7) | 92.5 | (82.6, 97.0) | 100.0 | - |
26 | Rifampin | 100.0 | - | 100.0 | - | 100.0 | - |
27 | Pyrazinamide | 92.1 | (89.3, 94.2) | 88.1 | (68.8, 96.1) | 100.0 | - |
28 | Ethambutol | 100.0 | - | 100.0 | - | 100.0 | - |
29 | Streptomycin | 98.3 | (96.8, 99.1) | 93.2 | (78.8, 98.0) | 92.0 | (78.7, 97.3) |
TREATMENT AND CASE MANAGEMENT | |||||||
Initial treatment regimen | |||||||
30 | Isoniazid | 98.2 | (96.8, 99.0) | 99.6 | (98.8, 99.9) | 98.6 | (97.2, 99.3) |
31 | Rifampin | 98.7 | (97.5, 99.4) | 99.9 | (99.7, 100.0) | 98.8 | (97.6, 99.4) |
32 | Pyrazinamide | 96.7 | (95.1, 97.8) | 98.1 | (96.7, 98.9) | 98.4 | (97.1, 99.1) |
33 | Ethambutol | 95.9 | (94.0, 97.2) | 98.8 | (97.4, 99.4) | 96.5 | (94.6, 97.8) |
34 | Streptomycin | 98.7 | (97.7, 99.3) | 40.3 | (16.3, 70.1) | 38.1 | (14.1, 69.9) |
35 | Sputum culture conversion documented | 85.4 | (81.1, 88.8) | 93.3 | (89.5, 95.7) | 87.8 | (83.0, 91.3) |
36 | Reason therapy stopped‡‡ | 97.9 | (96.4, 98.8) | ND | ND | ND | ND |
Completion of therapy | ND | ND | 97.8 | (96.0, 98.8) | 100.0 | - | |
Lost/uncooperative or refused therapy | ND | ND | 98.4 | (98.4, 98.4) | 62.9 | (46.1, 77.1) | |
Died | ND | ND | 99.2 | (96.6, 99.8) | 93.3 | (84.2, 97.4) | |
37 | Provider type | 73.4 | (69.8, 76.7) | ND | ND | ND | ND |
Health Department only (HD) | ND | ND | 74.7 | (69.7, 79.1) | 90.3 | (86.7, 93.0) | |
Private/Other only | ND | ND | 79.6 | (74.6, 83.9) | 80.0 | (74.2, 84.8) | |
Both HD and Private/Other | ND | ND | 38.6 | (26.4, 52.5) | 18.1 | (12.0, 26.4) | |
38 | Therapy administration | 48.6 | (44.4, 52.8) | ND | ND | ND | ND |
Directly Observed Therapy (DOT) only | ND | ND | 29.7 | (10.5, 60.4) | 1.1 | (0.4, 2.9) | |
Self-administered Therapy (SAT) only | ND | ND | 72.0 | (66.7, 76.7) | 88.3 | (83.1, 92.0) | |
Both DOT and SAT | ND | ND | 26.4 | (21.3, 32.2) | 82.7 | (73.1, 89.4) | |
39 | Final drug susceptibility testing done ‡‡ | 100.0 | - | 100.0 | - | 100.0 | - |
Results of final drug susceptibility testing††§§ | |||||||
40 | Isoniazid | 100.0 | - | 100.0 | - | 100.0 | - |
41 | Rifampin | 98.4 | (97.3, 99.0) | 92.6 | (79.7, 97.5) | 100.0 | - |
42 | Pyrazinamide | 90.5 | (59.5, 98.4) | - | - | - | - |
43 | Ethambutol | 90.3 | (59.0, 98.4) | - | - | - | - |
44 | Streptomycin | 100.0 | - | 100.0 | - | 100.0 | - |